116 related articles for article (PubMed ID: 34693691)
21. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.
Mikocka-Walus A; Prady SL; Pollok J; Esterman AJ; Gordon AL; Knowles S; Andrews JM
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012680. PubMed ID: 30977111
[TBL] [Abstract][Full Text] [Related]
22. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
23. Correlates of symptoms of depression and anxiety in chronic hemodialysis patients.
Bossola M; Ciciarelli C; Di Stasio E; Conte GL; Vulpio C; Luciani G; Tazza L
Gen Hosp Psychiatry; 2010; 32(2):125-31. PubMed ID: 20302985
[TBL] [Abstract][Full Text] [Related]
24. [The effect of 3-oxypyridine and succinic acid derivatives on the resistance to acute cerebral ischemia].
Volchegorskiĭ IA; Miroshnichenko II; Rassokhina LM; Faĭzullin RM; Priakhina KE; Malkin MP; Kalugina AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(12):123-127. PubMed ID: 25726791
[TBL] [Abstract][Full Text] [Related]
25. [ANTIANHEDONIC EFFECT OF 3-OXYPYRIDINE AND SUCCINIC ACID DERIVATIVES].
Volchegorskii IA; Miroshnichenko IY; Rassokhina LM; Faizullin RM; Pryakhina KE
Ross Fiziol Zh Im I M Sechenova; 2016 Nov; 102(11):1312-22. PubMed ID: 30193447
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of depressive symptoms in patients with coronary artery disease using the Montgomery Åsberg Depression Rating Scale.
Bunevicius A; Staniute M; Brozaitiene J; Pommer AM; Pop VJ; Montgomery SA; Bunevicius R
Int Clin Psychopharmacol; 2012 Sep; 27(5):249-55. PubMed ID: 22869009
[TBL] [Abstract][Full Text] [Related]
27. [Cerebroprotective effect of 3-oxypyridine and succinic acid derivatives in acute phase of alloxan-induced diabetes mellitus in rats].
Volchegorskiĭ IA; Rassokhina LM; Miroshnichenko IIu
Eksp Klin Farmakol; 2011; 74(5):17-25. PubMed ID: 21809693
[TBL] [Abstract][Full Text] [Related]
28. Post-detoxification drug treatment of anxiety and depression in alcohol addicts.
Hague WH; Wilson LG; Dudley DL; Cannon DS
J Nerv Ment Dis; 1976 May; 162(5):354-9. PubMed ID: 772172
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.
Hengartner MP; Jakobsen JC; Sørensen A; Plöderl M
PLoS One; 2020; 15(2):e0229381. PubMed ID: 32101579
[TBL] [Abstract][Full Text] [Related]
30. Rating depression severity in the elderly physically ill patient: reliability and factor structure of the Hamilton and the Montgomery-Asberg Depression Rating Scales.
Hammond MF
Int J Geriatr Psychiatry; 1998 Apr; 13(4):257-61. PubMed ID: 9646154
[TBL] [Abstract][Full Text] [Related]
31. The evaluation of depression in inpatients with HIV disease.
Cockram A; Judd FK; Mijch A; Norman T
Aust N Z J Psychiatry; 1999 Jun; 33(3):344-52. PubMed ID: 10442790
[TBL] [Abstract][Full Text] [Related]
32. THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial.
Vaccarino AL; Kalali AH; Blier P; Gilbert Evans S; Engelhardt N; Foster JA; Frey BN; Greist JH; Kobak KA; Lam RW; MacQueen G; Milev R; Müller DJ; Parikh SV; Placenza FM; Rizvi SJ; Rotzinger S; Sheehan DV; Sills T; Soares CN; Turecki G; Uher R; Williams JBW; Kennedy SH; Evans KR
Innov Clin Neurosci; 2020 Jul; 17(7-9):30-40. PubMed ID: 33520402
[No Abstract] [Full Text] [Related]
33. [The influence of 3-oxypyridine antioxidants on depression in patients with diabetes mellitus].
Volchegorskiĭ IA; Mester NV
Klin Med (Mosk); 2007; 85(2):40-5. PubMed ID: 17520888
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
[TBL] [Abstract][Full Text] [Related]
36. Measuring depression: comparison and integration of three scales in the GENDEP study.
Uher R; Farmer A; Maier W; Rietschel M; Hauser J; Marusic A; Mors O; Elkin A; Williamson RJ; Schmael C; Henigsberg N; Perez J; Mendlewicz J; Janzing JG; Zobel A; Skibinska M; Kozel D; Stamp AS; Bajs M; Placentino A; Barreto M; McGuffin P; Aitchison KJ
Psychol Med; 2008 Feb; 38(2):289-300. PubMed ID: 17922940
[TBL] [Abstract][Full Text] [Related]
37. Depression rating scales in Parkinson's disease: critique and recommendations.
Schrag A; Barone P; Brown RG; Leentjens AF; McDonald WM; Starkstein S; Weintraub D; Poewe W; Rascol O; Sampaio C; Stebbins GT; Goetz CG
Mov Disord; 2007 Jun; 22(8):1077-92. PubMed ID: 17394234
[TBL] [Abstract][Full Text] [Related]
38. The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence.
Hobden B; Schwandt ML; Carey M; Lee MR; Farokhnia M; Bouhlal S; Oldmeadow C; Leggio L
Alcohol Clin Exp Res; 2017 Jun; 41(6):1220-1227. PubMed ID: 28421616
[TBL] [Abstract][Full Text] [Related]
39. Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis.
Martinez-Martin P; Rojo-Abuin JM; Dujardin K; Pontone GM; Weintraub D; Forjaz MJ; Starkstein S; Leentjens AF
Eur J Neurol; 2013 Aug; 20(8):1198-203. PubMed ID: 23581431
[TBL] [Abstract][Full Text] [Related]
40. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
Bech P; Lönn SL; Overø KF
J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
